Showing 1 posts of 1 posts found.
Merck Serono’s new alpha-aminoamide safinamide has failed to reach its primary endpoint in a study with Parkinson’s disease patients. Merck …
NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
AstraZeneca’s Trixeo approved in EU for asthma
Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
ESTEVE CDMO adds $17.5m to Illinois expansion